London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Published 30/9/21. https://patentscope.wipo.int/search/en/detail.jsf?docId=US337428323&_cid=P11-KUDYNB-34180-1
only had patents 5 minutes
Yep. He knows the potential of FF. So do DSM but for some reason they can not land a biggy. I do hope someone from DSM will be at the AGM. Hope SL is there to. Would be nice to meet up with fellow shareholders after the AGM
ever
it is always worth remembering that Felix spent his PhD researching FF, so imho we are pushing against an open door @BH
W$
No, it's the equivalent of any other national standard, intended to inform the public that it is not some random untested product.
By Health have grown to the size they are by knowing how to promote their barnded products throughout that huge country
I assume the animal rights in China advertise that Rhino horn , shark fin, birds nest and bear bile are useless but tradition grinds on , it's a weird and wonderful place.
Yes true , I wonder how the Chinese look at Blue status ? maybe just having it means advertising is not required hence all the effort to get it ?
Maybe they don't have to?
But..... I am sure if they had spent goodness knows how many thousand or million Yuen on Studies, patents, Trademarks and scientific research like By-Health then I am sure they would have made more of an effort.
Do you really believe that By Health have self funded the extensive research and submissions to attain top level approval for Fruitflow in China just to hide it away in the backwoods?
Really?
Encouraging Gixer but like Healthplan who advertise a lot but they dont put Circulease out as a priority , you have to look for it.
I don't think you need to worry about By-Healths advertising budget.
"(3) During the reporting period, the company incurred a advertising expenses of 966 million, of which advertising
expenses on TV media were RMB 506 million, online advertising expenses were 212 million, and planning and
production expenses and others totaled RMB 248 million;"
https://upload-yyj.by-health.com/upload/files/0324160545898_2020%20Annual%20Report%20(Compact%20Edition).pdf
Hoping it's different this time but the LTHs have been through all this before with the fabled EU functional food milestone, that took 2 years and there was much promised on the back of it and we got SFA. If we are going to get anywhere then BH will have to spend a lot on advertising or persuade and already big product to add FF to it.
PXS is going to explode higher.Maybe i am naive as i just started to buy some, but the narrative in the FY RNS was clearly bullish! PXS seems to be on a path for a major upside move... excepts below:
"support the planned launch of a number of Fruitflow based products in the Chinese market, with potential volumes at a significant multiple of existing Fruitflow sales."
"The planned launch of Fruitflow based products in the Chinese market has been progressing well. "
"The total projected annual sales value of the prospective sales pipeline for Fruitflow continues to stand at a substantial multiple of existing annual sales."
"By-Health's planned launch of Fruitflow based products in the Chinese market has been progressing well. Clinical studies conducted in China are typically required to obtain the necessary regulatory clearances in China, and a significant investment in eight separate Fruitflow studies has been undertaken at By-Health's expense.
Five studies have been successfully completed in China, and two clinical studies and one animal study are currently ongoing.
The five completed studies showed excellent results in use for Fruitflow, and they provide strong evidence for By-Health in its regulatory submissions to the State Administration for Market Regulation (SAMR), China's top market regulator."
"By-Health currently expects to be in a position to complete the last of its eight studies and file its regulatory submission to the SAMR for Fruitflow in the first half of 2022, seeking to obtain a new permitted health function claim which would be in addition to the currently defined list of permitted health claims in China."
"If By-Health is successful in obtaining a new permitted health function claim, it is currently expected that this would result in some significant orders for Fruitflow, potentially at a multiple of current total sales values. The Company continues to believe that Fruitflow has the potential to play an important role in the Chinese cardiovascular health market."
From Daiken Biomedical.
https://www.daikenshop.com/product.php?ino=NEWDK200EC&code=4710255450395
Looks like a Test product
1 October 2021
Provexis plc
('Provexis' or the 'Company')
Grant of Share Options
Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces that it has today awarded a total of 10,000,000 options ('Options') over ordinary shares of 0.1 pence each in the Company ('Ordinary Shares') under the Provexis 2005 share option scheme to certain scientific, sales and marketing consultants to the Company.
These Options will have an exercise price of 0.80 pence, being the closing mid-market price on 30 September 2021. The Options are exercisable, subject to vesting, between 1 April 2024 and 10 years from the date of grant.
Following the issue of the new Options, the total number of Ordinary Shares under option which could be issued if all of the performance criteria are met is 178,500,000 Ordinary Shares, representing 8.1 per cent. of the Company's issued share capital.
For further information please contact:
Provexis plc
Ian Ford, CEO
Dawson Buck, Chairman
Tel: 07490 391888
Unless we get bp bluecap this month !!!!
Looking at results, although a improvement on the past going forward probably a couple of years at least until break even can be achieved.
Blue cap will help the cause but have no definite timeframe only probable months.
Not a top up price yet for me, but keeping a eye on in case it goes down to the .5 range.
I am sure IF had is reasons
IF chooses his words very carefully..
Number of BH studies has gone from nine to eight.
No mention of an APP now.
SAMR submissions are still in plural, suggest bp is still in the mix.
------
Jan 2021 By-Health has made a significant investment in nine separate studies in China, at its sole expense, in support of the Fruitflow based products which it plans to launch in China.
The five studies which have been completed by By-Health showed excellent results in use for Fruitflow, and provide strong evidence for By-Health in its regulatory submissions for Fruitflow
A Fruitflow App is also being developed, primarily for use on mobile device platforms
Sept 2021 By-Health has made a significant investment in eight separate studies in China, at its sole expense, in support of the Fruitflow based products which it plans to launch in China.
The five studies which have been completed by By-Health showed excellent results in use for Fruitflow, and provide strong evidence for By-Health in its regulatory submissions to the Chinese State Administration for Market Regulation (SAMR) for Fruitflow.
By-Health is now working on an extensive regulatory submission to the SAMR for Fruitflow, seeking to establish a new permitted health function claim for food ingredients such as Fruitflow that can demonstrate an anti-platelet effect, addressing the aberrant blood clots which can lead to heart attacks and strokes.
Wconfused
Seems like we have (or did have) £1m stuck in a business current account paying zero interest and nothing in a business savings account. According to the financials we got £113 as bank interest receivable. In fact we got more in FY2020 (£347) than in this RNS. Would have thought a lump of the £m would have been better off in an interest bearing account. Admitted it wouldn't be much but is it a sign of management incompetence?
Thanks Boring Bernie for a sensible post as per usual. You know I am bottom of the barrel faith wise here my concern is the time .The UK Gov is allowing Genetic crops to be grown and fed to Humans now , how long before they genetically modify something to promote platelet aggregation? I click on hold as I am under water , it is definitely not a buy , potential sales all too far away and too pie in the sky ATM.
wellsite, no problem, I didn't think you were but felt I had to clarify :)
Good question for Ford at the AGM I think. That and what is the timescale to get the health claim function.
colbaltblue, not sure what part of my post you think I am being optimistic about so its difficult to comment on what you see as "indisputable evidence to the contrary"
you say " If (and it's a big if) revenues flow from China"
Do you really think a company like By-Health would spend all that cash on studies and regulatory submissions if they didn't think they would see a return?
Sorry gix, I wasn’t having a go.
I think IF should provide clarification though
WS
kievsky, its unlikely but you never know.